Nanoparticle tracking analysis (NTA), a technique for characterizing nanoparticles with a size range of 10 – 2000 nm in liquids, has been widely used for aggregate characterization in protein/peptide formulations. As an expert in protein/peptide biopharmaceutical characterization, CD Formulation uses advanced NTA technology to help global customers gain a deep understanding of the stability and aggregate formation of protein formulations to support their formulation development and production process optimization.
NTA, also known as particle tracking analysis (PTA), is a technique used to measure the size distribution and concentration of nanoparticles. The technique uses the same theory as dynamic light scattering (DLS), combining the properties of laser light scattering microscopy and Brownian motion, allowing the measurement of protein particles ranging in size from about 50-100 nm to about 600-1,000 nm (depending on the light scattering intensity of the particles analyzed). The optimal particle concentration is typically between 10^6 and 10^10 particles/mL.
NTA has been recognized by numerous standards and guidance bodies, including ISO, ASTM, and EFSA, and focuses on submicron particle characterization.
It provides better size resolution for polydisperse samples than DLS. However, protein monomers are often too small to detect. For monodisperse samples, NTA is simple and fast to perform.
Fig. 1 Schematic setup of the nanoparticle tracking analysis.(Weber A, et al., 2019)
Like DLS, NTA analysis uses light scattering and Brownian motion models to determine particle size and particle size distribution.
In NTA analysis, the protein/peptide sample is illuminated by a laser beam, and the particle motion is tracked by scattering to evaluate the mean square displacement of the moving particles under Brownian motion in the sample chamber. Here, Brownian motion describes the random motion of nanoparticles in suspension. These motions are also called diffusion and are represented by the diffusion coefficient (D). By using the Stokes-Einstein equation, the particle diameter can be calculated and their hydrodynamic size can be obtained or the particle concentration can be calculated.
With decades of experience in supporting protein/peptide biopharmaceutical development and manufacturing using NAT technology, our team of highly qualified experts can provide a range of NAT-related services to accelerate the implementation and success of your project.
Our NAT technology supports all stages of your protein/peptide drug development and manufacturing - from early research to late-release testing under GMP.
Protein/peptide therapeutic formulations are very complex and protein aggregation or poor stability may occur during the following biomanufacturing processes.
Using NAT technology, our scientists are able to visualize and quantify in real time the protein aggregation dynamics of biotherapeutics under various stress conditions, including agitation, temperature, and added contaminants, to support the development and optimization of protein/peptide formulations.
Nanoparticle size distribution is key to the design and manufacture of targeted drug delivery. With NTA technology, our scientists are helping you develop and characterize a variety of innovative delivery systems, such as polymer nanoparticles, liposomes, solid lipid nanoparticles, etc.
Note*: NTA only analyzes protein/peptide samples prepared in aqueous suspension.
Published Data
Technology: NAT and DLS
Journal: Pharm Res.
IF: 3.5
Published: 2010
Results:
The authors demonstrated the performance of nanoparticle tracking analysis (NTA) in characterizing drug delivery nanoparticles and protein aggregates by comparing the technique to dynamic light scattering (DLS). Standard polystyrene beads ranging in size from 60 to 1,000 nm and their physical mixtures were analyzed using NTA and DLS. Drug delivery nanoparticles and protein aggregates were analyzed using NTA and DLS. The results showed that NTA can accurately analyze the size distribution of monodisperse and polydisperse samples that the presence of a small number of large particles (1,000 nm) does not generally affect the accuracy of NTA measurements, and that various population proportions can be easily detected and accurately measured. NTA can be used as a complement to DLS for the analysis of polydisperse nanoparticles and protein aggregates.
Fig. 2 Size distribution from NTA and DLS measurements of monodisperse polystyrene beads. (Filipe V, et al., 2010)
CD Formulation aims to provide a powerful analytical tool for aggregate characterization in protein/peptide formulations. Please feel free to contact us if you are interested in our services. Learn how our NTA technology can support the smooth implementation of your protein/peptide biopharmaceutical program.
References